内分泌学
内科学
氯沙坦
血管紧张素II
骨骼肌
线粒体生物发生
化学
血管紧张素受体
生物
医学
受体
线粒体
生物化学
作者
Soichi Takeda,Kosuke Kaji,Norihisa Nishimura,Masahide Enomoto,Yuki Fujimoto,Kōji Murata,Hiroaki Takaya,Hideto Kawaratani,Kei Moriya,Tadashi Namisaki,Takemi Akahane,Hitoshi Yoshiji
标识
DOI:10.1002/mnfr.202100526
摘要
Scope This study investigated the combined effect of the angiotensin II (AT‐II) receptor blocker losartan and branched‐chain amino acids (BCAAs) on skeletal muscle atrophy in rats with cirrhosis and steatohepatitis. Method and Results Fischer 344 rats are fed a choline‐deficient l ‐amino acid‐defined (CDAA) diet for 12 weeks and treated with oral losartan (30 mg kg −1 day −1 ) and/or BCAAs (Aminoleban EN, 2500 mg kg −1 day −1 ). Treatment with losartan and BCAAs attenuated hepatic inflammation and fibrosis and improved skeletal muscle atrophy and strength in CDAA‐fed rats. Both agents reduced intramuscular myostatin and pro‐inflammatory cytokine levels, resulting in inhibition of the ubiquitin–proteasome system (UPS) through interference with the SMAD and nuclear factor‐kappa B pathways, respectively. Losartan also augmented the BCAA‐mediated increase of skeletal muscle mass by promoting insulin growth factor‐I production and mitochondrial biogenesis. Moreover, losartan decreased the intramuscular expression of transcription factor EB (TFEB), a transcriptional inducer of E3 ubiquitin ligase regulated by AT‐II. In vitro assays illustrated that losartan promoted mitochondrial biogenesis and reduced TFEB expression in AT‐II‐stimulated rat myocytes, thereby potentiating the inhibitory effects of BCAAs on the UPS and caspase‐3 cleavage. Conclusion These results indicate that this regimen could serve as a novel treatment for patients with sarcopenia and liver cirrhosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI